Utrogestan Special Precautions

The treatment, when administered in accordance with the recommended schedules, is not contraceptive.
The menstrual cycle may be shortened and/or bleeding may occur if the treatment sequence is initiated too early, particularly before cycle day 15.
In the presence of uterine bleeding, Utrogestan must not be prescribed until a definite cause has been established, preferably via endometrial investigation.
Treatment should be suspended at the onset of any: Eye disorders, such as loss of vision, diplopia, vascular lesions of the retina.
Venous thromboembolisms or thrombotic events, regardless of the territory.
Severe headaches.
Patients with a history of thrombophlebitis should be closely monitored.
More than half of early spontaneous abortions (miscarriages) are caused by genetic disorders. Furthermore, they may also be caused by infectious manifestations and mechanical disorders; in which case, the sole result of administrating progesterone would be to delay expulsion of a dead ovum. Progesterone administration must therefore only be reserved for cases where corpus luteum secretion is inadequate.
During HRT involving oestrogens, administration of progesterone over a minimum of 12 days per cycle is strongly recommended.
Effects on Ability to Drive and Use Machines: Oral: Attention should be drawn to the risks of drowsiness and/or dizziness associated with the oral use of this product, particularly in the case of patients intending to drive or operate machinery. Intake of capsules at bedtime will avoid such problems.